A topical experimental treatment called "Klasukotron" showed promising results in reducing male hair loss, becoming the first treatment to directly target hair follicles without affecting body-level hormones.
Cosmo Pharmaceuticals in Ireland conducted two extensive clinical trials named Scalp 1 and Scalp 2, with 1465 men from the United States and Europe participating.
Participants received either the topical solution or a placebo, while efficacy was evaluated by counting hairs in specific areas of the scalp.
Mechanism of Action
Klasukotron works by inhibiting the effect of the DHT hormone directly in the hair follicles, the hormone responsible for the genetic shrinking of follicles, thus addressing the root cause of male baldness without exposure to general hormonal risks, as reported by Fox News.
Trial Results
In the Scalp 1 trial, the treatment showed a 539% improvement compared to the placebo.
In the Scalp 2 trial, the improvement was 168%.
Combining the results of both trials showed a strong statistical significance and clear alignment with the actual hair count.
Dr. Maria Hordinsky stated that the results reveal Klasukotron's 5% solution's ability to achieve significant hair growth with "virtually no hormonal exposure."
Participant Experience
Participants reported a noticeable improvement in hair density and growth, positively reflecting on their personal satisfaction and appearance. Dr. Mark Siegel commented, "There is currently no cream or lotion effective in treating baldness. Minoxidil has limited effect, and this new treatment could be an important step in clinical use."
Safety and Side Effects
Side effects were limited to mild skin irritation, with side effect rates similar to the placebo group.
Nevertheless, experts warn of the potential for rare skin allergies or a minor effect on the adrenal gland due to the anti-androgen nature of the drug.
Next Steps
The company plans to continue safety monitoring for an additional 12 months until spring 2026, in preparation for submitting approval requests in the United States and Europe.
Upon obtaining regulatory approvals, Klasukotron will become the first topical treatment to directly target DHT at the follicles, potentially representing a significant shift in the treatment of male baldness after decades of relying on options with limited efficacy.
